BRPI1006766B8 - sais de meglumina, trometamina e arginina de um inibidor de dihidroorotato dehidrogenase, composição farmacêutica e uso dos mesmos - Google Patents
sais de meglumina, trometamina e arginina de um inibidor de dihidroorotato dehidrogenase, composição farmacêutica e uso dos mesmosInfo
- Publication number
- BRPI1006766B8 BRPI1006766B8 BRPI1006766A BRPI1006766A BRPI1006766B8 BR PI1006766 B8 BRPI1006766 B8 BR PI1006766B8 BR PI1006766 A BRPI1006766 A BR PI1006766A BR PI1006766 A BRPI1006766 A BR PI1006766A BR PI1006766 B8 BRPI1006766 B8 BR PI1006766B8
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutically acceptable
- groups
- meglumine
- tromethamine
- pharmaceutical composition
- Prior art date
Links
- 229940083266 Dihydroorotate dehydrogenase inhibitor Drugs 0.000 title 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 title 1
- 125000000637 arginyl group Chemical class N[C@@H](CCCNC(N)=N)C(=O)* 0.000 title 1
- 239000003363 dihydroorotate dehydrogenase inhibitor Substances 0.000 title 1
- 229960003194 meglumine Drugs 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 title 1
- 229960000281 trometamol Drugs 0.000 title 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 150000003839 salts Chemical class 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 150000003862 amino acid derivatives Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/79—Acids; Esters
- C07D213/80—Acids; Esters in position 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
sal composição farmaceuticamente aceitável, combinação, uso de um sal e método de tratamento de um indivíduo que sofre com uma condição patológica ou doença. a presente invenção refere-se a novos sais de adição cristalinos, farmaceuticamente aceitáveis solúveia em àgua de (i) uma amina contendo um ou mais grupos hidroxila e/ou carboxilico com (ii) derivado de ácido amino nicotínicos de fprmulas (i) em que ra, rb, rc e rd independentemente representam halogênio, grupos alquila c1-c4 que podem ser opcionalmente substituídos por 1, 2 ou 3 substituintes selecionados a partir de átomos de halogênio e grupos hidróxi, e grupos alcoxí c1-c4 que podem ser opcionalmente substituidos por 1, 2, ou 3 substituintes selecionados apartir de átomos de halogênio e grupos hidróxi, e solvatos farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09382031.4 | 2009-03-13 | ||
| EP09382031A EP2228367A1 (en) | 2009-03-13 | 2009-03-13 | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as DHODH inhibitors |
| PCT/EP2010/001550 WO2010102826A1 (en) | 2009-03-13 | 2010-03-11 | Addition salts of amines containing hydroxyl and/or carboxylic groups with amino nicotinic acid derivatives as dhodh inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BRPI1006766B1 BRPI1006766B1 (pt) | 2021-03-23 |
| BRPI1006766B8 true BRPI1006766B8 (pt) | 2021-05-25 |
Family
ID=40677683
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1006766A BRPI1006766B8 (pt) | 2009-03-13 | 2010-03-11 | sais de meglumina, trometamina e arginina de um inibidor de dihidroorotato dehidrogenase, composição farmacêutica e uso dos mesmos |
Country Status (34)
| Country | Link |
|---|---|
| US (1) | US20120014918A1 (pt) |
| EP (2) | EP2228367A1 (pt) |
| JP (1) | JP5674685B2 (pt) |
| KR (1) | KR101674699B1 (pt) |
| CN (1) | CN102348689B (pt) |
| AR (1) | AR075738A1 (pt) |
| AU (1) | AU2010223528B2 (pt) |
| BR (1) | BRPI1006766B8 (pt) |
| CA (1) | CA2754804C (pt) |
| CL (1) | CL2011002216A1 (pt) |
| CO (1) | CO6420337A2 (pt) |
| CY (1) | CY1114418T1 (pt) |
| DK (1) | DK2406225T3 (pt) |
| EA (1) | EA022350B1 (pt) |
| EC (1) | ECSP11011365A (pt) |
| ES (1) | ES2428746T3 (pt) |
| HR (1) | HRP20130851T1 (pt) |
| IL (1) | IL214519A (pt) |
| ME (1) | ME01564B (pt) |
| MX (1) | MX2011009146A (pt) |
| MY (1) | MY155140A (pt) |
| NZ (1) | NZ594493A (pt) |
| PE (1) | PE20120171A1 (pt) |
| PL (1) | PL2406225T3 (pt) |
| PT (1) | PT2406225E (pt) |
| RS (1) | RS52949B (pt) |
| SG (1) | SG173823A1 (pt) |
| SI (1) | SI2406225T1 (pt) |
| SM (1) | SMT201300104B (pt) |
| TW (1) | TWI428127B (pt) |
| UA (1) | UA105786C2 (pt) |
| UY (1) | UY32467A (pt) |
| WO (1) | WO2010102826A1 (pt) |
| ZA (1) | ZA201105744B (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
| EP2135610A1 (en) | 2008-06-20 | 2009-12-23 | Laboratorios Almirall, S.A. | Combination comprising DHODH inhibitors and methotrexate |
| EP2239256A1 (en) | 2009-03-13 | 2010-10-13 | Almirall, S.A. | Sodium salt of 5-cyclopropyl-2-{[2-(2,6-difluorophenyl)pyrimidin-5-yl]amino}benzoic acid as DHODH inhibitor |
| EP2314577A1 (en) | 2009-10-16 | 2011-04-27 | Almirall, S.A. | Process for manufacturing 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid |
| EP2444088A1 (en) * | 2010-10-22 | 2012-04-25 | Almirall, S.A. | Amino derivatives for the treatment of proliferative skin disorders |
| EP2594271A1 (en) * | 2011-11-21 | 2013-05-22 | Almirall, S.A. | 2-[(3,5-difluoro-3'-methoxy-1,1'-biphenyl-4-yl)amino]nicotinic acid for the treatment of psoriasis. |
| KR101251851B1 (ko) | 2011-11-30 | 2013-04-10 | 현대자동차주식회사 | Ｉｓｇ 시스템 및 이의 제어방법 |
| TW201350467A (zh) * | 2012-05-08 | 2013-12-16 | Teva Pharma | Ｎ－乙基－４－羥基－１－甲基－５－（甲基（２，３，４，５，６－五羥基己基）胺基）－２－側氧－ｎ－苯基－１，２－二氫喹啉－３－甲醯胺 |
| TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
| US20160051679A1 (en) * | 2013-04-12 | 2016-02-25 | Actavis Group Ptc Ehf. | Pemetrexed Formulation |
| WO2018136009A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| WO2018136010A1 (en) | 2017-01-20 | 2018-07-26 | Aslan Pharmaceuticals Pte Ltd | Combination therapy |
| CN108530310B (zh) * | 2017-03-02 | 2025-01-28 | 中国科学院上海药物研究所 | 2-(取代苯杂基)芳香甲酸类fto抑制剂，其制备方法及其应用 |
| CN110662539B (zh) | 2017-04-24 | 2023-08-15 | 奥里吉恩探索技术有限公司 | 三取代的苯并三唑衍生物作为二氢乳清酸加氧酶抑制剂的使用方法 |
| KR20200123137A (ko) | 2018-02-20 | 2020-10-28 | 아지오스 파마슈티컬스 아이엔씨. | 삼치환 벤조트리아졸 유도체의 사용 방법 |
| CN112969699A (zh) | 2018-10-09 | 2021-06-15 | 亚狮康私人有限公司 | 瓦利替尼的丙二酸盐 |
| SG11202106526UA (en) * | 2018-12-21 | 2021-07-29 | Les Laboratoires Servier Sas | Crystalline and salt forms of an organic compound and pharmaceutical compositions thereof |
| KR20230116779A (ko) * | 2020-10-15 | 2023-08-04 | 아슬란 파마슈티컬스 피티이 엘티디 | 디히드로오로테이트 헤하이드로즈네이즈(dhodh) 저해제를 이용한 자가면역 질환의 치료 |
| CN114907267A (zh) * | 2021-02-08 | 2022-08-16 | 中国科学院上海药物研究所 | 用于抗肿瘤的药物组合 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3839344A (en) * | 1973-03-28 | 1974-10-01 | Schering Corp | N-methyl d-glucamine salt of 2(2'-methyl-3'-trifluoromethylanilino)nicotinic acid |
| GB9804343D0 (en) | 1998-02-27 | 1998-04-22 | Univ Cardiff | Chemical compounds |
| AU775157B2 (en) * | 1999-06-10 | 2004-07-22 | Warner-Lambert Company Llc | Method of inhibiting amyloid protein aggregation and imaging amyloid deposits |
| ATE396719T1 (de) | 2001-04-05 | 2008-06-15 | Aventis Pharma Inc | Verwendung von (z)-2-cyano-3-hydroxy-but-2- ensäure-(4'-trifluoromethylphenyl)-amid zur behandlung der multiplen sklerose |
| WO2003006424A1 (en) | 2001-07-10 | 2003-01-23 | 4Sc Ag | Novel compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| JP2004099586A (ja) * | 2002-05-21 | 2004-04-02 | Sumitomo Pharmaceut Co Ltd | ジヒドロオロテートデヒドロゲナーゼ阻害剤 |
| AU2003300530A1 (en) | 2002-12-23 | 2004-07-14 | 4Sc Ag | Dhodh-inhibitors and method for their identification |
| WO2004056746A1 (en) | 2002-12-23 | 2004-07-08 | 4Sc Ag | Cycloalkene dicarboxylic acid compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| US20070219224A1 (en) | 2004-05-21 | 2007-09-20 | Uab Research Foundation, The | Compositions and Methods Relating to Pyrimidine Synthesis Inhibitors |
| WO2006022442A1 (ja) | 2004-08-24 | 2006-03-02 | Santen Pharmaceutical Co., Ltd. | ジヒドロオロテートデヒドロゲナーゼ阻害活性を有する新規複素環アミド誘導体 |
| AU2005295511A1 (en) | 2004-10-19 | 2006-04-27 | Aventis Pharmaceuticals Inc. | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| JP2007015952A (ja) * | 2005-07-06 | 2007-01-25 | Shionogi & Co Ltd | ナフタレン誘導体 |
| ES2303758B1 (es) | 2006-02-20 | 2009-08-13 | Laboratorios Almirall S.A. | Nuevos derivados de piridin-3-amina. |
| ES2301380B1 (es) | 2006-08-09 | 2009-06-08 | Laboratorios Almirall S.A. | Nuevos derivados de 1,7-naftiridina. |
| ES2319596B1 (es) | 2006-12-22 | 2010-02-08 | Laboratorios Almirall S.A. | Nuevos derivados de los acidos amino-nicotinico y amino-isonicotinico. |
| UY31272A1 (es) * | 2007-08-10 | 2009-01-30 | Almirall Lab | Nuevos derivados de ácido azabifenilaminobenzoico |
-
2009
- 2009-03-13 EP EP09382031A patent/EP2228367A1/en not_active Withdrawn
-
2010
- 2010-02-24 UY UY0001032467A patent/UY32467A/es active IP Right Grant
- 2010-03-08 TW TW099106617A patent/TWI428127B/zh active
- 2010-03-11 EP EP10708932.8A patent/EP2406225B1/en active Active
- 2010-03-11 US US13/256,349 patent/US20120014918A1/en not_active Abandoned
- 2010-03-11 HR HRP20130851AT patent/HRP20130851T1/hr unknown
- 2010-03-11 NZ NZ594493A patent/NZ594493A/xx unknown
- 2010-03-11 ME MEP-2013-106A patent/ME01564B/me unknown
- 2010-03-11 BR BRPI1006766A patent/BRPI1006766B8/pt active IP Right Grant
- 2010-03-11 SG SG2011060811A patent/SG173823A1/en unknown
- 2010-03-11 WO PCT/EP2010/001550 patent/WO2010102826A1/en active Application Filing
- 2010-03-11 PE PE2011001599A patent/PE20120171A1/es active IP Right Grant
- 2010-03-11 RS RS20130394A patent/RS52949B/en unknown
- 2010-03-11 MY MYPI2011004300A patent/MY155140A/en unknown
- 2010-03-11 KR KR1020117021314A patent/KR101674699B1/ko active Active
- 2010-03-11 AU AU2010223528A patent/AU2010223528B2/en active Active
- 2010-03-11 MX MX2011009146A patent/MX2011009146A/es active IP Right Grant
- 2010-03-11 CN CN201080011530.6A patent/CN102348689B/zh active Active
- 2010-03-11 SI SI201030344T patent/SI2406225T1/sl unknown
- 2010-03-11 AR ARP100100741A patent/AR075738A1/es not_active Application Discontinuation
- 2010-03-11 JP JP2011553360A patent/JP5674685B2/ja active Active
- 2010-03-11 PL PL10708932T patent/PL2406225T3/pl unknown
- 2010-03-11 CA CA2754804A patent/CA2754804C/en active Active
- 2010-03-11 DK DK10708932.8T patent/DK2406225T3/da active
- 2010-03-11 PT PT107089328T patent/PT2406225E/pt unknown
- 2010-03-11 UA UAA201111802A patent/UA105786C2/uk unknown
- 2010-03-11 ES ES10708932T patent/ES2428746T3/es active Active
- 2010-03-11 EA EA201101297A patent/EA022350B1/ru unknown
-
2011
- 2011-08-04 ZA ZA2011/05744A patent/ZA201105744B/en unknown
- 2011-08-08 IL IL214519A patent/IL214519A/en active IP Right Grant
- 2011-09-01 CO CO11112338A patent/CO6420337A2/es not_active Application Discontinuation
- 2011-09-08 CL CL2011002216A patent/CL2011002216A1/es unknown
- 2011-09-30 EC EC2011011365A patent/ECSP11011365A/es unknown
-
2013
- 2013-09-18 CY CY20131100818T patent/CY1114418T1/el unknown
- 2013-09-23 SM SM201300104T patent/SMT201300104B/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1006766B8 (pt) | sais de meglumina, trometamina e arginina de um inibidor de dihidroorotato dehidrogenase, composição farmacêutica e uso dos mesmos | |
| EA201300052A1 (ru) | [1,8]нафтиридиновые производные | |
| RS54260B1 (en) | AMINODIHYDROTIAZINE DERIVATIVES AS BACE INHIBITORS FOR ALZHEIMER DISEASE TREATMENT | |
| BR112013029240A2 (pt) | derivados deuterados do ivacaftor | |
| EA201592055A1 (ru) | 11-гидроксилпроизводные желчных кислот и их аминокислотные конъюгаты в качестве модуляторов фарнезоидных х-рецепторов | |
| GEP20166432B (en) | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh | |
| BR112014010420A2 (pt) | inibidores de pak para o tratamento de distúrbios proliferativos celulares | |
| UA110838C2 (uk) | 4-(8-МЕТОКСИ-1-(1-МЕТОКСИПРОПАН-2-ІЛ)-2-(ТЕТРАГІДРО-2H-ПІРАН-4-ІЛ)-1H-ІМІДАЗО[4,5-c]ХІНОЛІН-7-ІЛ)-3,5-ДИМЕТИЛІЗОКСАЗОЛ ТА ЙОГО ЗАСТОСУВАННЯ ЯК ІНГІБІТОРА БРОМОДОМЕНУ | |
| PH12013501941A1 (en) | Pyrazolospiroketone derivatives for use as acetyl - coa carboxylase inhibitors | |
| UA102336C2 (uk) | N1-ПІРАЗОЛСПІРОКЕТОНИ ЯК ІНГІБІТОРИ АЦЕТИЛ-СоА-КАРБОКСИЛАЗ | |
| BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
| BR112015015477A2 (pt) | derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk | |
| EA201000947A1 (ru) | Производные тиазола, применимые в качестве ингибиторов киназы pi3 | |
| MX2009005691A (es) | Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i. | |
| BRPI0718966B8 (pt) | composto, composição farmacêutica, inibidor plk1 e agente antitumoral | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| EA200870302A1 (ru) | 1,3-диоксанкарбоновые кислоты | |
| BR112014001369A2 (pt) | derivados de ácido hidroxâmico de heteroarila e uso dos mesmos no tratamento, melhora ou prevenção de doença viral | |
| BRPI0807597B8 (pt) | composição farmacêutica, e, uso de um derivado de pirazina ou um sal do mesmo e um ou mais inibidor(es) de neuraminidase em combinação | |
| DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
| BR112014008412A2 (pt) | derivados de pirimidin-4-ona e sua utilização no tratamento, na melhora ou na prevenção de uma doença viral | |
| MX2008010884A (es) | Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1. | |
| MA32240B1 (fr) | Inhibiteurs de désacétylases b à base d'hydroxamate | |
| EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 | |
| MX340033B (es) | Derivados heterobiciclicos como inhibidores del virus de la hepatitis c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/03/2021, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 11/03/2010 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |